FDA Approves VYALEV — AbbVie Inc.

# FDA Approves AbbVie's VYALEV for Parkinson's Disease Treatment AbbVie Inc. received FDA approval for VYALEV (foscarbidopa/foslevodopa) subcutaneous injection, a novel formulation designed to provide continuous dopaminergic therapy for advanced Parkinson's disease patients, potentially capturing market share from existing infusion therapies and oral treatments. The approval expands AbbVie's neurology portfolio and positions the company to compete in the growing segment of continuous delivery Parkinson's treatments.